No Data
No Data
Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences
Promising Results of CD388 Lead to Buy Rating for Cidara Therapeutics
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
Cidara Therapeutics Announces Two Presentations On Innovative Drug-Fc Conjugate, CD388, At The 2024 OPTIONS XII For The Control Of Influenza Conference
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza